Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early Drug Launches Off To a Strong Start So Far in 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

2012 was a record year for drug approvals; now many of those drugs approved last year and this year are launching and off to a strong start in the first three months of 2013.

You may also be interested in...

Pharmaceutical Spending Fell Slightly; A First, Says IMS Institute

IMS report on U.S. medical trends highlights the trends in patient spending and shows that over one-third of spending was concentrated in the top five therapeutic classes in 2012.

Astellas/Medivation Strengthen Case For Xtandi In Advance Of Second Filing

New PSA data from the AFFFIRM trial in post-chemo patients indicate prostate cancer drug Xtandi works equally well regardless how advanced the disease, a meaningful finding for heavily pretreated patients like those in the trial. Interim rPFS data from a chemo-naïve study will be available in the second half of 2013, but a supplemental filing most certainly will wait for overall survival results.

Biogen Idec Undercuts Gilenya With $55,000 Yearly Price For Tecfidera

The company expects dimethyl fumarate’s strong efficacy and favorable safety and tolerability profile to be an advantage against other oral multiple sclerosis drugs.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts